Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Efficacy of TACE in combination with sorafenib versus sorafenib or TACE alone for advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials (RCTs).

Muhammad Ayyan, Cara Mohammed, Roshan Afshan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16259

e16259 Background: Hepatocellular Carcinoma (HCC) is the sixth fastest-growing type of cancer globally and the fourth largest cause of death related to ca...

Real-world treatment patterns and time-to-treatment discontinuation among advanced ALK-positive non-small cell lung cancer patients.

Rahul Mudumba, Xiaofan Liu, Ian Davis et al. Jun 01, 2025 pp. 8603-8603 10.1200/jco.2025.43.16_suppl.8603

8603 Background: Advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is typically treated with ALK tyrosine kinase inhib...

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings.

Raajit Rampal, Samantha Eiffert, Michael Marrone et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23274

e23274 Background: Anemia is a major clinical burden for patients (pts) with myelofibrosis (MF) with a need for transfusions affecting quality of life and...

Telemedicine-enabled synchronous medical oncology and home hospice visits.

Sara Dost, Ross Albert, Todd J. Alekshun et al. Jun 01, 2025 pp. 12100-12100 10.1200/jco.2025.43.16_suppl.12100

12100 Background: Hospice is underutilized at end-of-life by patients with cancer. Among the barriers to earlier acceptance of hospice may be the perceive...

AI-driven prediction of post-transplant survival and stratification of HCC recurrence risk.

Junho Song, Jihyun Kim, CholMin Kang et al. Jun 01, 2025 pp. 4114-4114 10.1200/jco.2025.43.16_suppl.4114

4114 Background: Traditional selection criteria (e.g., Milan, UCSF) and scoring systems (MELD/PELD) for liver transplant eligibility in hepatocellular car...

Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.

Mohamad Adham Salkeni, David Sommerhalder, Andrae Lavon Vandross et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2669

TPS2669 Background: LILRB2 is an inhibitory receptor expressed on myeloid cells, including tumor-associated macrophages, which binds to HLA-class I protei...

Management of loop electrosurgical excision procedure with positive margins.

Christopher M. Mayer, Emily E. O'Brien, Osarumen W. Egiebor et al. Jun 01, 2025 pp. 5534-5534 10.1200/jco.2025.43.16_suppl.5534

5534 Background: Loop Electrosurgical Excision Procedure (LEEP) is a primary management for preinvasive cervical disease. While often successful, around 1...

Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).

Qian Shi, George J. Chang, Levi D. Pederson et al. Jun 01, 2025 pp. 3520-3520 10.1200/jco.2025.43.16_suppl.3520

3520 Background: Recent analyses highlight nonhierarchical outcomes using the 8 th Edition AJCC staging system for CC. For instanc...

Acute bowel symptoms following relugolix and stereotactic body radiotherapy for localized prostate cancer.

Srinivas Sowmiyanarayanan, Sarthak Shah, Omar Anwar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17086

e17086 Background: Androgen deprivation therapy improves cancer control in combination with prostate radiotherapy. Relugolix, an oral GnRH receptor antago...

Prevalence of and factors associated with financial toxicity among gastrointestinal cancer patients in Pakistan.

Sehar Salim Virani, Tayyab Siddiqui, Fatima Shaukat et al. Jun 01, 2025 pp. 1616-1616 10.1200/jco.2025.43.16_suppl.1616

1616 Background: Financial toxicity (FT) impacts cancer care in low- and middle-income countries (LMICs), affecting treatment adherence and quality of lif...

The impact of targeted therapies on overall survival in advanced malignancy.

Elizabeth Crenshaw, Neeharika Srivastava Makani Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15171

e15171 Background: Next-generation sequencing (NGS) analyzes DNA and RNA of malignant tumors through tissue or blood. NGS testing provides data about diag...

Post-hoc analysis evaluating selinexor maintenance therapy in patients with <i>TP53</i> wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.

Jalid Sehouli, Ignace Vergote, Erika P. Hamilton et al. Jun 01, 2025 pp. 5608-5608 10.1200/jco.2025.43.16_suppl.5608

5608 Background: At primary analysis of the phase 3 study of selinexor (SEL) maintenance treatment in patients (pts) with advanced/recurrent endometrial c...

Impact of SGLT2 inhibitors in patients with multiple myeloma and diabetes mellitus.

Jia Yi Tan, Aravinthan Vignarajah, Yong Hao Yeo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19515

e19515 Background: The prevalence of diabetes mellitus (DM) is significantly higher in patients with multiple myeloma (MM) compared to the general populat...

Pregnancy and miscarriage before epithelial ovarian cancer (EOC) diagnosis in patients carrying germline <i>BRCA1/BRCA2</i> pathogenic variants.

Tancredi Didier Bazan Russo, Mattia Puglisi, Elga Adriana Cipolla et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22516

e22516 Background: Several case-control studies have been performed to understand the prognostic impact of pregnancy after breast cancer in patients carry...

Efficacy and safety of trastuzumab deruxtecan in HER-2 expressing solid tumors: A systematic review and meta-analysis.

Muhammad Ansab, Shree Rath, Ahmed Raza et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15021

e15021 Background: HER2 expressing solid tumors represent a diverse group of malignancies with expression of protein HER2, including mostly breast but als...

Induction pembrolizumab plus cisplatin and 5-FU chemotherapy followed by chemoradiotherapy in locally advanced squamous cell cancer of oropharynx, hypopharynx or larynx: Results of multicenter prospective phase II study.

Ilya Pokataev, Olesia Stativko, Sergey Kravtsov et al. Jun 01, 2025 pp. 6070-6070 10.1200/jco.2025.43.16_suppl.6070

6070 Background: Chemoradiation with cisplatin or induction chemotherapy with docetaxel, platinum agent and 5-FU are associated with high toxicity. We hyp...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).

Kartik Sehgal, Jesus Corral Jaime, Steven Francis Powell et al. Jun 01, 2025 pp. 3010-3010 10.1200/jco.2025.43.16_suppl.3010

3010 Background: IB6, a tumor-associated membrane protein, is overexpressed in many solid tumors, including non-small cell lung cancer (NSCLC) and head an...

Role of the combination of 3 T whole-body MRI and 18F-FDG PET/CT in the management of multiple myeloma and smoldering myeloma: The new era of imaging.

Claudio Cerchione, Davide Bezzi, Delia Cangini et al. Jun 01, 2025 pp. 7560-7560 10.1200/jco.2025.43.16_suppl.7560

7560 Background: FDG-PET/TC and MRI are both imaging diagnostic tools adopted in diagnosis and/or response assessment in multiple myeloma (MM) which can b...

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Eziafa Oduah, Scott Joseph Antonia, Jeffrey J. Clarke et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8118

TPS8118 Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in early-stage surgically resec...

Alcohol abuse among adults with esophageal cancer and impact on outcomes of esophagectomy.

Archit Gupta, Yara Alnaber, Alex Tannous et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16056

e16056 Background: Recent reports from the American Cancer Society confirmed a rising incidence, mortality rate, and burden of esophageal cancer in the Un...

Relative lymphocyte percentage as a predictive biomarker for immune checkpoint inhibitor in metastatic melanoma: A real-world analysis.

Furkan Bahar, Yu Chang, Cho Han Chiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21549

e21549 Background: Response variability to immune checkpoint inhibitors (ICIs) necessitates the identification of predictive biomarkers. Relative lymphocy...

Impact of <i>TP53</i> somatic mutations on prognosis in endometrial cancer: A systematic review and meta-analysis.

Nayara Rozalem Moretti, Pedro Henrique De Souza Wagner, Gustavo Tadeu Freitas Uchôa Matheus et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17618

e17618 Background: Endometrial cancer (EC) is the sixth most common cancer affecting women globally and is projected to become the fourth leading cause of...

Outcomes of veterans diagnosed with chronic myeloid leukemia in the tyrosine kinase inhibitor era.

Matthew Harry Rosenthal, Stevephen Hung, Omar Shukri Yaghi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18567

e18567 Background: Since the development and approval of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL, the treatment landscape for chronic myeloid...

Preclinical and early stage clinical study on the regulation of tumor-associated inflammatory factor IL-6 by traditional Chinese medicine compound formula BDL.

Yangyang Geng, Yu Zhao, Zhui Ke et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15131

e15131 Background: IL-6 has been found to be highly expressed in a wide range of cancer species and is thought to be associated with poor prognosis and tr...

A prospective, randomized control trial of concurrent paclitaxel and carboplatin along with radiotherapy versus concurrent cisplatin along with radiotherapy in carcinoma cervix patients at a tertiary care hospital of central India.

Praghnya Subhash Tejale, Prachi Ketanbhai Padia, Ashok Diwan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5620

TPS5620 Background: In India, cervical cancer accounted for 9.0% of all cancers and 18.3% (127,526) of new cases in 2022 as per GLOBOCAN. It is leading ca...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page